Forgot your password?

Forgot your username?

database > company
PhysioGenix, Inc.
10437 Innovation Drive
Wauwatosa, WI 53226 USA
phone:414-431-6600 ext 105
fax:
Symbol Private
Founded 0
Employees
www.physiogenix.com
Research Sector
Summary Description
Physiogenix provides preclinical research services for diabetes, behavioral and cardiovascular diseases.
Management
Brian D. Curry, Ph. D., President and Chief Executive Officer; Richard J. Roman, Ph. D., Chief Scientific Officer, Board of Directors; Gregory P. Meier, J.D., Executive Vice President; Steven H. Nye, Ph. D., Director of Research Programs; Annette Dahly-Vernon, Ph. D., Senior Study Director; Darin L. Evans, M.S., Director of Operations; Mary Burrell, Vice-President of Business Development
Keywords
Diabetes, Behavioral and Cardiovascular Diseases, Pharmacodynamic, Pharmacokinetic

Comment | Printable Version | Modify profile |
Updated: Jan. 24, 2009

Description
Physiogenix provides preclinical research services for diabetes, behavioral and cardiovascular diseases. Our services include in vivo efficacy, pharmacodynamic (PD) and pharmacokinetic (PK) studies coupled with our proprietary research models. Our team of experts deliver fast, cost-effective preclinical research services to pharmaceutical, biopharma and medical device companies. Our team of highly trained PhD and MS scientists engage in the design and execution of your preclinical drug development program using our AALAC approved animal facilities, proprietary animal models, and in vivo surgical expertise. This results are fast delivery, cost-effective preclinical research services for pharmaceutical, biopharma and medical device companies.
Products / Services
Product and Service Offering * Pharmacokinetic and pharmacodynamic dosing of client drug compounds. * Surgical procedures including uninephrectomy; implantation of femoral catheter, jugular catheter, telemetry devices or osmotic pumps. * Acute and chronic dosing protocols by oral gavage; subcutaneous, IP, intramuscular and tail vein injections; osmotic pump implantation. * Gross necropsy that includes detection of drug-induced abnormalities, organ removal and preservation for histological or molecular analysis. * Histopathology that includes organ preservation, generation of tissue slices, staining and scoring by certified pathologists. * Statistical analysis of data using SigmaSTAT, PRIZM and Excel. * Data interpretation by experts in cardiovascular and renal physiology. * Follow-up consulting.